Patents by Inventor David Uehling

David Uehling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF
    Publication number: 20240092763
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting or blocking NUAK kinase, such as cancers and fibrosis.
    Type: Application
    Filed: January 7, 2022
    Publication date: March 21, 2024
    Inventors: Rima Al-Awar, Liliana Attisano, Methvin Isaac, Yong Liu, David Smil, David Uehling, Jeff Wrana
  • THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF
    Publication number: 20240025887
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting or blocking NUAK kinase, such as cancers and fibrosis.
    Type: Application
    Filed: January 7, 2022
    Publication date: January 25, 2024
    Inventors: Rima Al-Awar, Liliana Attisano, Methvin Isaac, Yong Liu, David Smil, David Uehling, Jeff Wrana
  • SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20230219926
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: May 6, 2022
    Publication date: July 13, 2023
    Inventors: Rima AL-AWAR, Carlos Armando ZEPEDA-VELAZQUEZ, Gennady PODA, Methvin ISAAC, David UEHLING, Brian WILSON, Babu JOSEPH, Yong LIU, Pandiaraju SUBRAMANIAN, Ahmed MAMAI, Michael PRAKESCH, Julia Katheleen STILLE
  • Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction
    Patent number: 11518764
    Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: December 6, 2022
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
  • UNSATURATED HETEROCYCLOALKYL AND HETEROAROMATIC ACYL HYDRAZONE LINKERS, METHODS AND USES THEREOF
    Publication number: 20220267281
    Abstract: The present application is directed to compounds of Formula (I), (II), (III) or (IV) compositions comprising these compounds, methods for their preparation and their uses, for example, as acyl hydrazone linkers, which can link two chemical entities together for further use as medicaments and/or diagnostics.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 25, 2022
    Inventors: Ahmed MAMAI, Anh My CHAU, David Uehling
  • Compounds and methods for treating nematode infections
    Patent number: 11364234
    Abstract: The present application relates to the treatment of nematode infections.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: June 21, 2022
    Assignees: The Governing Council of the University of Toronto, Ontario Institute for Cancer Research (OICR)
    Inventors: Peter Roy, Sean Harrington, Jacob Pyche, Daniel Kulke, Genna M. Luciani, Andrew Burns, Mark Lautens, Rachel Ross, David Uehling
  • Substituted carboxamides as inhibitors of WDR5 protein-protein binding
    Patent number: 11319299
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: May 3, 2022
    Assignee: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai, Michael Prakesch, Julia Kathleen Stille
  • Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof
    Patent number: 11242351
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 8, 2022
    Assignee: ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
  • Substituted carboxamides as inhibitors of WDR5 protein-protein binding
    Patent number: 11174250
    Abstract: The present application is directed to compounds of Formula I: compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 16, 2021
    Assignee: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai
  • TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
    Publication number: 20210053978
    Abstract: The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Application
    Filed: December 21, 2018
    Publication date: February 25, 2021
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Iain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling
  • INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20200385371
    Abstract: The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: September 6, 2018
    Publication date: December 10, 2020
    Applicant: Propellon Therapeutics Inc.
    Inventors: Rima Al-Awar, Methvin Isaac, Joseph Babu, Yong Liu, Ahmed Mamai, Gennady Poda, Pandiaraju Subramanian, David Uehling, Brian Wilson, Carlos Armando Zepeda-Velazquez
  • INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
    Publication number: 20200331921
    Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Application
    Filed: February 6, 2019
    Publication date: October 22, 2020
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Lain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
  • INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20190119264
    Abstract: The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: March 1, 2017
    Publication date: April 25, 2019
    Applicant: PROPELLON THERAPEUTICS INC.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai
  • INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING
    Publication number: 20190112290
    Abstract: The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.
    Type: Application
    Filed: March 1, 2017
    Publication date: April 18, 2019
    Applicant: PROPELLON THERAPEUTICS INC.
    Inventors: Rima Al-Awar, Carlos Armando Zepeda-Velazquez, Gennady Poda, Methvin Isaac, David Uehling, Brian Wilson, Babu Joseph, Yong Liu, Pandiaraju Subramanian, Ahmed Mamai, Michael Prakesch, Julia Kathleen Stille
  • 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors
    Publication number: 20080051395
    Abstract: The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.
    Type: Application
    Filed: December 6, 2005
    Publication date: February 28, 2008
    Inventors: David Uehling, Kirk Stevens, Scott Dickerson, Alex Waterson, Philip Harris, Douglas Sammond, Robert Hubbard, Holly Emerson, Joseph Wilson
  • Chemical compounds
    Publication number: 20060148887
    Abstract: The present invention discloses compounds of Formula I. The present invention also discloses beta-3 agonists of formula I and methods for treating beta-3 mediated diseases and condition using the compounds of formula I, in particular methods for treating diabetes or obesity.
    Type: Application
    Filed: February 21, 2006
    Publication date: July 6, 2006
    Inventors: David Deaton, Barry Shearer, David Uehling
  • Thienopyrimidine compounds as protein tyrosine kinase inhibitors
    Publication number: 20050009845
    Abstract: The present invention relates to thienopyrmidine compounds of formula (I) (one of A1 and A2 is S and the other is CH), salts thereof, as well as use and preparation of the same. These compounds are inhibitors of various protein tyrosine kinases (PTKs) of the ErbB family and consequently are useful in the treatment of disorders mediated by aberrant activity of such kinases.
    Type: Application
    Filed: December 13, 2002
    Publication date: January 13, 2005
    Inventors: Thomas Caferro, Stanley Chamberlain, Kelly Donaldson, Philip Harris, Michael Gaul, David Uehling, Dana Vanderwall